



AAR:kam 6/17/04 4239-67017-01 285447
E-339 2003/0-US-01

Ifw

PATENT

Attorney Reference Number 4239-67017-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Brechbiel *et al.*

Application No. 10/756,948

Filed: January 13, 2004

Confirmation No. 3278

For: METHODS FOR IMAGING THE
LYMPHATIC SYSTEM USING
DENDRIMER-BASED CONTRAST
AGENTS

Examiner: To be assigned

Art Unit: 3736

Attorney Reference No. 4239-67017-01

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney
for Applicant(s)

Date Mailed June 17, 2004

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- ☒ Information Disclosure Statement
 - ☒ Form 1449 and non-U.S. patent and patent application references cited thereon.
- ☒ The Director is hereby authorized to charge any additional fees that may be required to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Aden A. Rehms, Ph.D.

Registration No. 55,935

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446
cc: Docketing



AAR 06/17/04 4239-67017-01 285261

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Brechbiel *et al.*

Application No. 10/756,948

Filed: January 13, 2004

Confirmation No. 3278

For: METHODS FOR IMAGING THE
LYMPHATIC SYSTEM USING
DENDRIMER-BASED CONTRAST
AGENTS

Examiner: To be assigned

Art Unit: 3736

Attorney Reference No. 4239-67017-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney
for Applicant(s)

Date Mailed June 17, 2004

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Since the present application was filed after June 30, 2003, copies of United States patents and United States published patent applications do not have to be provided to the Patent Office. This requirement of 37 C.F.R. § 1.98(a)(2)(i) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on August 5, 2003 (1276 OG 55). However, Applicants will provide copies of such patents upon request.


Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS.

However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to our deposit account as indicated on the Transmittal Letter.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.


Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Aden A. Rehms, Ph.D.
Registration No. 55,935

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing



JUN 21 2004

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	4239-67017-01
Application Number	10/756,948
Filing Date	January 13, 2004
First Named Inventor	Brechbiel
Art Unit	3736
Examiner Name	To be assigned

U.S. PATENT DOCUMENTS

NOTE: If this application was filed after June 30, 2003, copies of United States patents and United States published patent applications do not have to be provided to the Patent Office. This requirement of 37 C.F.R. § 1.98(a)(2)(i) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on August 5, 2003 (1276 OG 55).

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		6,274,713	8/14/01	Sieving <i>et al.</i>
		6,045,776	4/4/00	Platzek <i>et al.</i>
		5,958,373	9/28/99	Garrity <i>et al.</i>
		5,914,095	6/22/99	Watson
		5,874,061	2/23/99	Schmitt-Willich <i>et al.</i>
		5,834,020	11/10/98	Margerum <i>et al.</i>
		5,759,518	6/02/98	Schmitt-Willich <i>et al.</i>
		5,714,166	2/3/98	Tomalia <i>et al.</i>
		5,560,929	10/1/96	Hedstrand <i>et al.</i>
		5,527,524	6/18/96	Tomalia <i>et al.</i>
		5,434,287	7/18/95	Gansow <i>et al.</i>
		5,428,154	6/27/95	Gansow <i>et al.</i>
		5,364,613	11/15/94	Sieving <i>et al.</i>
		5,338,532	8/16/94	Tomalia <i>et al.</i>
		5,292,868	3/8/94	Subramanian
		5,246,692	9/21/93	Gansow <i>et al.</i>

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Attorney Docket Number		4239-67017-01
				Application Number		10/756,948
				Filing Date		January 13, 2004
				First Named Inventor		Brechbiel
				Art Unit		3736
				Examiner Name		To be assigned
		US 2002/0004032		1/10/02	Liu	
FOREIGN PATENT DOCUMENTS						
Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee	
		European	EP0882454A2	12/9/98		
		European	EP0736059B1	12/1994		
		European	EP0497926B1	6/1998		
		European	EP0416033B1	3/1996		
		PCT	WO 00/72037	11/2000		
		PCT	WO 95/17451	6/1995		
		PCT	WO 95/09564	4/1995		
		PCT	WO 93/14147	7/1993		
		PCT	WO 93/06868	4/1993		
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS				
		Alazraki <i>et al.</i> , "Sentinel node staging of early breast cancer using lymphoscintigraphy and the intraoperative gamma detecting probe," <i>Radiologic Clinics of North America</i> 39(5):947-956, September 2001.				
		Aldrich Handbook of Fine Chemicals and Laboratory Equipment, pp. 486 and 1521, (2000-2001).				
		Bourne, <i>et al.</i> , "Evaluation of the Effects of Intravascular MR Contrast Media (Gadolinium Dendrimer) on 3D Time of Flight Magnetic Resonance Angiography of the Body," <i>JMRI</i> , pp 305-310, 1995.				
		Bremer <i>et al.</i> , "Optical-based molecular imaging: contrast agents and potential medical applications," <i>Eur. Radiol.</i> 13(2):231-243, 2003, Epub Aug. 13, 2002.				
		Bulte <i>et al.</i> , "Dysprosium-DOTA-PAMAM dendrimers as macromolecular T2 contrast agents, preparation and relaxometry," <i>Investigative Radiology</i> 33(11):841-845, 1998.				
EXAMINER SIGNATURE:				DATE CONSIDERED:		
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.						

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-67017-01
		Application Number	10/756,948
		Filing Date	January 13, 2004
		First Named Inventor	Brechbiel
		Art Unit	3736
		Examiner Name	To be assigned
		Caravan <i>et al.</i> , "Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications," <i>Chem. Rev.</i> , pp. 2293-2352, 1999.	
		Chang <i>et al.</i> , "Permselectivity of The Glomerular Capillary Wall to Macromolecules – II. Experimental Studies in Rats Using Neutral Dextran," <i>Biophysical Journal</i> , Vol. 15, pp. 887-906, 1975.	
		Eichman <i>et al.</i> , "Imaging of gold dendrimer nanocomposites in cells," <i>Mat. Res. Soc. Symp. Proc.</i> , Vol. 676, pp. Y9.3.1-Y9.3.11, 2001.	
		Friedrich, "MRI of the breast: state of the art," <i>Eur. Radiol.</i> 8(5):707-725, 1998. (abstract)	
		Gallardo <i>et al.</i> , "Enhancement of intramammary lymph nodes with lymphoid hyperplasia: a potential pitfall in breast MRI," <i>Eur. Radiol.</i> 8(9):1662-1665, 1998. (abstract)	
		Guasch <i>et al.</i> , "Charge Selectivity of the Glomerular Filtration Barrier in Healthy and Nephrotic Humans," <i>J. Clin Invest.</i> , Vol. 92, pp. 2274-2282, 1993.	
		Harika <i>et al.</i> , "Macromolecular intravenous contrast agent for MR lymphography: characterization and efficacy studies," <i>Radiology</i> 198(2):365-370, February 1996. (abstract)	
		Ishiyama <i>et al.</i> , "Sentinel lymph node after intramammary injection of superparamagnetic iron oxide," <i>Department of Radiology, Akita University School of Medicine</i> 62(13):744-746, November 2002. (abstract)	
		Kinoshita <i>et al.</i> , "Inflammatory intramammary lymph node mimicking the malignant lesion in dynamic MRI: a case report," <i>Clin. Imaging.</i> 26(4):258-262, July-August 2002. (abstract)	
		Kobayashi <i>et al.</i> , "Comparison of dendrimer-based macromolecular contrast agents for dynamic micro-magnetic resonance lymphangiography," <i>Magnetic Resonance in Medicine</i> 50:758-766, October 2003.	
		Kobayashi, <i>et al.</i> , "Comparison of the Macromolecular MR Contrast Agents with Ethylenediamine-Core versus Ammonia-Core Generation-6 Polyamidoamine Dendrimer," <i>Bioconjugate Chem.</i> , 12(1):100-107, 2001.	
		Kobayashi <i>et al.</i> , "Dynamic Micro-Magnetic Resonance Imaging of Liver Micrometastasis in Mice with a Novel Liver Macromolecular Magnetic Resonance Contrast Agent DAB-Am64-(1B4M-Gd) ₆₄ ," <i>Cancer Research</i> 61:4966-4970, 2001.	
		Kobayashi, <i>et al.</i> , "Evaluation of the in Vivo Biodistribution of Indium-111 and Yttrium-88 Labeled Dendrimer-1B4M-DTPA and Its Conjugation with Anti-Tac Monoclonal Antibody," <i>Bioconjugate Chem.</i> 10(1):103-111, 1999.	

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-67017-01
		Application Number	10/756,948
		Filing Date	January 13, 2004
		First Named Inventor	Brechbiel
		Art Unit	3736
		Examiner Name	To be assigned
		Kobayashi <i>et al.</i> , "Lymphatic drainage imaging of breast cancer in mice by micro-magnetic resonance lymphangiography using a nano-size paramagnetic contrast agent," <i>J. Natl. Cancer Inst.</i> 96(9):703-708, 2004. (abstract and preprint)	
		Kobayashi <i>et al.</i> , "Macromolecular MRI Contrast Agents with Small Dendrimers: Pharmacokinetic Differences between Sizes and Cores," <i>Bioconjugate Chem.</i> 14:388-394, 2003.	
		Kobayashi <i>et al.</i> , "Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent," <i>Cancer Research</i> 63:271-276, January 15, 2003.	
		Kobayashi <i>et al.</i> , "Micro-MR angiography of normal and intratumoral vessels in mice using dedicated intravascular MR contrast agents with high generation of polyamidoamine dendrimer core: reference to pharmacokinetic properties of dendrimer-based MR contrast agents," <i>Journal of Magnetic Resonance Imaging</i> 14:705-713, 2001.	
		Kobayashi <i>et al.</i> , "Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity," <i>European Journal of Nuclear Medicine</i> , Vol. 27(9), 2000.	
		Kobayashi <i>et al.</i> , "Novel Intravascular Macromolecular MRI Contrast Agent With Generation-4 Polyamidoamine Dendrimer Core: Accelerated Renal Excretion With Coinjection of Lysine," <i>Magnetic Resonance in Medicine</i> 46:457-464, 2001.	
		Kobayashi <i>et al.</i> , "Novel Liver Macromolecular MR Contrast Agent With a Polypropylenimine Diaminobutyl Dendrimer Core: Comparison to the Vascular MR Contrast Agent With the Polyamidoamine Dendrimer Core," <i>Magnetic Resonance in Medicine</i> 46:795-802, 2001.	
		Kobayashi <i>et al.</i> , "The Pharmacokinetic Characteristics of Glycolated Humanized Anti-Tacs Fabs are Determined by Their Isoelectric Points," <i>Cancer Research</i> 59:422-430, 1999.	
		Kobayashi <i>et al.</i> , "Positive Effects of Polyethylene Glycol Conjugation to Generation-4 Polyamidoamine Dendrimers as Macromolecular MR Contrast Agents," <i>Magnetic Resonance in Medicine</i> 46:781-788, 2000.	
		Kobayashi <i>et al.</i> , "Renal tubular damage detected by dynamic micro-MRI with a dendrimer-based magnetic resonance contrast agent," <i>Kidney International</i> 61:1980-1985, 2002.	
		Kobayashi <i>et al.</i> , "3D-Micro-MR Angiography of Mice Using Macromolecular MR Contrast Agents With Polyamidoamine Dendrimer Core With Reference to Their Pharmacokinetic Properties," <i>Magnetic Resonance in Medicine</i> 45:454-460, 2001.	

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-67017-01
		Application Number	10/756,948
		Filing Date	January 13, 2004
		First Named Inventor	Brechbiel
		Art Unit	3736
		Examiner Name	To be assigned
		Konda <i>et al.</i> , "Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts," <i>Magnetic Resonance Materials in Physics, Biology and Medicine</i> 12:104-113, 2001.	
		Liberman <i>et al.</i> , "Ductal enhancement on MR imaging of the breast," <i>AJR Am. J. Roentgenol.</i> 181(2):519-525, August 2003. (abstract)	
		Lin <i>et al.</i> , "Novel near-infrared cyanine fluorochromes: synthesis, properties, and bioconjugation," <i>Bioconjug. Chem.</i> 13(3):605-610, 2002. (abstract)	
		Lin <i>et al.</i> , "Synthesis and properties of sulfhydryl-reactive near-infrared cyanine fluorochromes for fluorescence imaging," <i>Mol. Imaging.</i> 2(2):87-92, 2003. (abstract)	
		"Magnetic resonance imaging, signa 1.5T, 1.0T open breast phased array coil," http://www.gemedicalsystems.com/rad/mri/products/mri/mri_breastpa.html , printed 1/12/2004.	
		Mahmood <i>et al.</i> , "Near-infrared optical imaging of protease activity for tumor detection," <i>Radiology</i> 213:866-870, 1999.	
		Malik <i>et al.</i> , "Dendrimer-platinate: a novel approach to cancer chemotherapy," <i>Anti-Cancer Drugs</i> 10:767-776, 1999.	
		Malik <i>et al.</i> , "Dendrimers: Relationship Between Structure and Biocompatibility In Vitro, and Preliminary Studies on The Biodistribution of ¹²⁵ I-labelled polyamidoamine dendrimers in vivo," <i>J. Controlled Release</i> 65:133-148, 2000.	
		Michel <i>et al.</i> , "Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement," <i>Radiology</i> 225(2):527-536, November 2002. (abstract)	
		Murray <i>et al.</i> , "Dynamic contrast enhanced MRI of the axilla in women with breast cancer: comparison with pathology of excised nodes," <i>Br. J. Radiol.</i> 75(891):220-228, March 2002. (abstract)	
		Mussurakis <i>et al.</i> , "Prediction of axillary lymph node status in invasive breast cancer with dynamic contrast-enhanced MR imaging," <i>Radiology</i> 203(2):317-321, 1997. (abstract)	
		Ntziachristos <i>et al.</i> , "Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging," <i>Eur. Radiol.</i> 13(1):195-208, 2003, Epub July 19, 2002.	
		Rankin, "MRI of the breast," <i>The British Journal of Radiology</i> 73:806-818, 2000.	
		Sato <i>et al.</i> , "Pharmacokinetics and Enhancement Patterns of Macromolecular MR Contrast Agent With Various Sizes of Polyamidoamine Dendrimer Cores," <i>Magnetic Resonance in Medicine</i> 46:1169-1173, 2001.	

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	4239-67017-01
		Application Number	10/756,948
		Filing Date	January 13, 2004
		First Named Inventor	Brechbiel
		Art Unit	3736
		Examiner Name	To be assigned
		Staatz <i>et al.</i> , "T1-weighted MR-lymphography after intramammary administration of Gadomer-17 in pigs," <i>Dept. of Diagnostic Radiology, Aachen University of Technology, Berlin, Germany</i> , 174(2):242, February 2002.	
		Suga <i>et al.</i> , "Localization of breast sentinel lymph nodes by MR lymphography with a conventional gadolinium contrast agent," <i>Acta Radiologica</i> 44:35-42, 2003.	
		Tajarobi <i>et al.</i> , "Transport of poly amidoamine dendrimers across Madin-Darby canine kidney cells," <i>International Journal of Pharmaceutics</i> 215:263-267, 2001.	
		Takashima <i>et al.</i> , "Papillary thyroid carcinoma: MR diagnosis of lymph node metastasis," <i>AJNR Am. J. Neuroradiol.</i> 19:509-513, March 1998.	
		Torchia <i>et al.</i> , "Interstitial MR lymphangiography for the detection of sentinel lymph nodes," <i>Journal of Surgical Oncology</i> 78:151-157, 2001.	
		Torchia and Misselwitz, "Combined MR lymphangiography and MR imaging—guided needle localization of sentinel lymph nodes using gadomer-17," <i>AJR</i> 179:1561-1565, December 2002.	
		Wiener, "Dendrimer-Based Metal Chelates: A New Class of Magnetic Resonance Imaging Contrast Agents," <i>MRM</i> 31:1-8, 1994.	
		Williams <i>et al.</i> , "Future directions in imaging of breast diseases," <i>Radiology</i> 206(2):297-300, 1998. (abstract)	
		Wörner and Mülhaupt, "Polynitrile- and Polyamine-Functional Poly(trimethylene imine) Dendrimers," <i>Angew. Chem. Int. Ed. Engl.</i> 32(9):1306-1308, 1993.	

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	